The MCV Switch Study

Led by the MCV Switch Impact Consortium (MSIC)

Launch: August 2024 | Duration: 21 Months | Focus: MCV Coverage

Study Overview

Measles containing vaccine (MCV) presentation switches - impact, experiences, cost-effectiveness, and lessons learned.

Primary Objective: To conduct a comprehensive impact assessment on the switch from MCV 10-dose vial to 5-dose vial presentation on MCV 1 and MCV 2 coverage at the national and subnational levels in two African countries namely Zambia (retrospective study) and Ethiopia (prospective study).

We are working with Zambian and Ethiopian academic partners to address the dire lack of context-specific evidence related to implementation of vaccine switches in Africa, which is a barrier to the work of National Immunization and Technical Advisory Groups (NITAGs) on the continent.

Consortium Partners

  • University of Cape Town (UCT), Vaccines for Africa Initiative (VACFA), South Africa – Lead partner
  • National Centre for Immunization Research and Surveillance (NCIRS), Australia
  • Linksbridge, USA
Research Team: Headed by Assoc. Prof Benjamin Kagina, with co-investigator Dr Elizabeth Oduwole.
Funded by: Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance Logo